Drug Profile
Research programme: cancer therapeutics - Therapure Biopharma/BioVectra
Latest Information Update: 16 Jun 2014
Price :
$50
*
At a glance
- Originator BioVectra; Therapure Biopharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Jun 2014 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 18 Jan 2013 BioVectra has been acquired by Questcor Pharmaceuticals
- 06 May 2011 No development reported - Preclinical for Cancer in Canada (unspecified route)